Cancer is not a single mutation, but it is fundamentally a disease driven by mutations. Every cancer begins when changes in a cell’s DNA cause it to grow and divide without the normal controls. Most tumors carry between one and five of these critical mutations, though some carry more than ten. The relationship between cancer and mutations is direct: without genetic changes, whether inherited or acquired over a lifetime, cancer does not develop.
How Mutations Lead to Cancer
Your cells have built-in systems that control when they grow, when they divide, and when they die. Two categories of genes do most of this work. The first, called proto-oncogenes, act like accelerators. They produce proteins that tell cells to grow and divide in response to the right signals. The second, called tumor suppressor genes, act like brakes. They slow division down or trigger a cell to self-destruct when something goes wrong.
Cancer develops when mutations knock these systems off balance. A mutation in a proto-oncogene can jam the accelerator into the “on” position, turning it into an oncogene that drives constant growth. The Ras gene family is one of the most common examples: a single change to one DNA letter can lock the Ras protein into a permanently active state, pushing cells to multiply nonstop. Importantly, only one copy of a proto-oncogene needs to be mutated for this to happen.
Tumor suppressor genes work differently. The most well-known, TP53, produces a protein that monitors cell division and halts it when DNA damage is detected. When both copies of a tumor suppressor gene are knocked out, there’s nothing left to pump the brakes. This “two-hit” requirement means tumor suppressor genes are harder to disable than proto-oncogenes, but when they go, the consequences are severe.
Sometimes the damage isn’t a simple point mutation. Entire sections of chromosomes can get rearranged. In chronic myelogenous leukemia, pieces of chromosomes 9 and 22 swap places, fusing two genes together into a hybrid that produces an overactive signaling protein. This single chromosomal translocation is enough to initiate the disease.
How Many Mutations Does Cancer Need?
Not every mutation in your DNA contributes to cancer. Cells accumulate thousands of harmless “passenger” mutations over a lifetime. What matters are “driver” mutations, the ones that actually give a cell a growth advantage. A large-scale analysis published in the Proceedings of the National Academy of Sciences estimated that tumors carry an average of roughly two driver mutations in known cancer genes, with a range of one to five depending on cancer type.
Some cancers need very little genetic disruption. Testicular cancer and thyroid carcinoma can arise from a single driver mutation. Others require a longer accumulation. Colorectal cancer averages about three driver mutations, and bladder and endometrial cancers can require four or five. Some estimates for endometrial and colorectal cancers put the number above ten when counting all positively selected mutations across the genome, not just those in well-characterized cancer genes.
This is why cancer becomes more common with age. Each year your cells divide, there’s another chance for a driver mutation to appear. The classic model of colorectal cancer illustrates this stepwise process: an early mutation disables a gene involved in cell signaling, later mutations activate growth-promoting genes, and additional hits accumulate as the tumor progresses from a small polyp to an invasive cancer over a period of years or decades.
Where the Mutations Come From
About 90% of cancers are caused by mutations that a person acquires during their lifetime, not mutations they were born with. Up to 10% of cancers are linked to inherited genetic changes passed down from a parent. The rest arise from three main sources: environmental damage, errors during normal cell division, and a combination of both.
Environmental exposures leave recognizable fingerprints in a cell’s DNA. Ultraviolet radiation from sunlight, for instance, causes a distinctive pattern of C-to-T mutations, including characteristic double-letter changes (CC to TT) that show up frequently in melanoma. Tobacco smoke leaves a different signature: chemicals like benzo(a)pyrene in cigarette smoke react with specific DNA bases, producing a pattern dominated by C-to-A mutations. Sequencing studies of bronchial cells in smokers have found a several-fold increase in total mutation load compared to non-smokers, with most of that increase matching the known tobacco smoke signature.
Even without environmental exposures, your cells make copying errors every time they divide. The body’s DNA repair machinery catches most of these mistakes, but some slip through. Over decades, these random errors are the single largest source of cancer-causing mutations, which is a major reason cancer incidence rises sharply after age 50.
Epigenetic Changes: Cancer Without New Mutations
Mutations aren’t the only way genes get switched on or off in cancer. Epigenetic changes alter how genes are read without changing the DNA sequence itself. Think of it as the difference between rewriting a sentence and taping over it so it can’t be read. The sentence is still there, but it’s been silenced.
In cancer, this often involves abnormal methylation patterns. Chemical tags called methyl groups can pile up on the control regions of tumor suppressor genes, effectively shutting them down. Changes to the proteins that package DNA (histones) can have similar effects, making stretches of the genome either more or less accessible to the cell’s reading machinery. These epigenetic shifts can silence genes critical for controlling cell growth and promoting normal cell death.
What makes epigenetic changes particularly significant is that they frequently occur early in cancer development and can sometimes precede and outnumber actual genetic mutations. They’re also reversible, which makes them an active area of treatment development, since silenced genes can potentially be switched back on.
Inherited vs. Acquired Mutations
When a cancer-related mutation is inherited, it’s present in every cell of the body from birth. This doesn’t mean cancer is guaranteed, but it means one of the necessary “hits” is already in place. People with an inherited mutation in a tumor suppressor gene, for example, only need to lose the second copy in a single cell for that safety brake to fail completely, rather than needing two separate events in the same cell.
The interplay between inherited and acquired mutations can also shape how aggressive a cancer becomes. Research on Ewing sarcoma, a bone cancer, has shown that the inherited genetic background of a patient can modulate how powerfully a cancer-driving mutation activates downstream genes. Two patients with the same core mutation can have very different tumor growth rates and drug responses because of inherited variation in their regulatory DNA. This interaction between the genome you’re born with and the mutations your tumor acquires helps explain why the same type of cancer can behave so differently from one person to the next.
How Mutation Knowledge Shapes Treatment
Understanding that cancer is driven by specific mutations has transformed how it’s treated. Rather than relying solely on chemotherapy that kills all rapidly dividing cells, doctors can now match treatments to the exact mutations in a patient’s tumor. Lung cancers driven by mutations in the EGFR gene, for example, can be treated with drugs designed to block that specific overactive protein. Melanomas carrying a BRAF mutation respond to a different class of targeted drugs. Colorectal cancers with certain mutations have their own matched therapies.
Identifying these mutations has also moved beyond traditional tissue biopsies. Blood tests can now detect fragments of tumor DNA circulating in the bloodstream. This approach was first authorized in Europe in 2014 for identifying EGFR mutations in lung cancer patients, and it has since expanded to track mutations in breast, colorectal, and prostate cancers. These tests can guide initial treatment decisions, monitor whether a tumor is responding to therapy, and catch new mutations that signal the cancer is becoming resistant to a drug, all from a standard blood draw.
The practical impact is significant. In breast cancer, blood-based monitoring of a mutation in the ESR1 gene has allowed doctors to switch therapies early when resistance emerges, producing meaningful clinical benefit. In lung cancer, serial blood tests tracking a specific resistance mutation have proven reliable enough to guide decisions about when to change treatment regimens. The ability to read a tumor’s mutational profile, and to re-read it as the tumor evolves, is now a core part of cancer care for many types of the disease.